Key result
Anthracyclin-based chemotherapy was associated with a 277% increase in NT-proBNP levels compared to healthy volunteers and significant course-to-course QT interval prolongation.
Why the study?
Does anthracyclin-based chemotherapy acutely increase NT-proBNP and prolong QTc intervals in patients with malignancies?
Population
26 patients with various malignancies receiving doxorubicin-based chemotherapy and 14 healthy controls…
Comparison
Anthracyclin-based chemotherapy administered… vs Healthy controls and baseline measurements.
Design
Cohort
Follow-up
Up to 6 months after completion of therapy, and 24 hours…
Authors
Loading...
May support serial NT-proBNP and QTc monitoring during anthracycline therapy; hypothesis-generating pending outcome validation.
Observational (n=40)
No
Does anthracyclin-based chemotherapy acutely increase NT-proBNP and prolong QTc intervals in patients with malignancies?
Effect estimate: 277% higher (95% CI 86-661)
Absolute Event Rate: 148.9% vs 39.5%
p-value: p=<0.001
NT-proBNP and QTc interval may serve as sensitive early biomarkers for the course-to-course evaluation of anthracyclin-induced cardiotoxicity.
Broeyer et al. (2008) conducted an observational in Cancer (patients receiving anthracyclin-based chemotherapy) (n=40). Anthracyclin-based chemotherapy vs. Healthy volunteers was evaluated on NT-proBNP levels compared to healthy volunteers (277% higher, 95% CI 86-661, p=<0.001). Anthracyclin-based chemotherapy was associated with a 277% increase in NT-proBNP levels compared to healthy volunteers and significant course-to-course QT interval prolongation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: